SynthesisArthritis care & research2013
Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.
Synthesis in Arthritis care & research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.Arthritis care & research · 2018Pooled it
- Trends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.Seminars in arthritis and rheumatism · 2020Article
- First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study.BMC rheumatology · 2020Article
- Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.Journal of managed care & specialty pharmacy · 2019Article
- Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.Journal of managed care & specialty pharmacy · 2019Observational
- Challenges in Implementing Treat-to-Target Strategies in Rheumatology.Rheumatic diseases clinics of North America · 2019Review
- A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries.Current opinion in rheumatology · 2017Review
- Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures.Arthritis care & research · 2016Article
- Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009.The Permanente journal · 2016Article
- Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.Arthritis research & therapy · 2015Observational
- Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.Seminars in arthritis and rheumatism · 2015Observational
- Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.The Journal of rheumatology · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo report and synthesize patterns of disease-modifying antirheumatic drug (DMARD) use reported in observational studies of patients with established and early rheumatoid arthritis (RA) after publication of the American College of Rheumatology guidelines promoting universal DMARD use.
methodsWe searched PubMed for full-length articles in English published between January 1, 2002 and October 1, 2012 that examined DMARD use. The data abstracted from articles included the patient characteristics, country of study, time period studied, patient source, and treating physician type. Study quality was assessed using a modified Newcastle-Ottawa Quality Assessment Scale.
resultsWe reviewed 1,287 abstracts; 98 full-length articles were selected for additional review and 27 studies describing 28 cohorts of patients were included. Twelve studies described data from cohorts of patients with established RA, and DMARD use in this group of studies ranged from 73-100%. Five studies described data from patients sourced through administrative data and demonstrated consistently lower DMARD use, ranging from 30-63%. Three studies conducted population-based surveys to define cases of RA where DMARD use ranged from 47-73%. Eight studies investigated patients with early RA. DMARD use among patients followed by rheumatologists ranged from 77-98%, whereas DMARD use reported for patients seen by a mix of physicians was significantly lower (39-63%).
conclusionDMARD use in studies from RA cohorts or registries (in which patients were followed by rheumatologists) ranged from 73-100%, compared with 30-73% in studies from administrative data or population-based surveys (in which patients were not necessarily receiving rheumatology subspecialty care).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.